Alnylam

Biotech companies Alnylam, Dicerna settle trade secrets case
Biotech companies Alnylam, Dicerna settle trade secrets case
Reuters
Alnylam
Dicerna
trade secrets
gene silencing
Flag link:
Why Pfizer's Big Win Is Bad News for Alnylam and Ionis
Why Pfizer's Big Win Is Bad News for Alnylam and Ionis
Yahoo/Motley Fool
Pfizer
Alnylam
Ionis Pharmaceuticals
tafamidis
inotersen
Patisiran
Flag link:
Pfizer's rare heart disease drug succeeds in late-stage study
Pfizer's rare heart disease drug succeeds in late-stage study
Yahoo/Reuters
Pfizer
clinical trials
tafamidis
transthyretin cardiomyopathy
rare disease
Alnylam
Ionis Pharmaceuticals
Flag link:
3 Blockbuster Drug Launches to Watch In 2018
3 Blockbuster Drug Launches to Watch In 2018
Motley Fool
drug launches
Gilead Sciences
HIV
Biktarvy
Alnylam
Sanofi
Patisiran
Epidiolex
GW Pharma
Flag link:
Regeneron, Alnylam partner to turn discovery into new drugs for NASH
Regeneron, Alnylam partner to turn discovery into new drugs for NASH
Biopharma Dive
Regeneron
Alnylam
NASH
R&D
drug discovery
Flag link:
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
Endpoints
drug launches
Hemlibra
Roche
Biktarvy
Gilead Sciences
Ozempic
Novo Nordisk
Erleada
JNJ
Shingrix
GSK
Patisiran
Alnylam
Sanofi
Epidiolex
GW Pharma
Aimovig
Amgen
Novartis
lanadelumab
Shire
Elagolix
AbbVie
Steglatro
Pfizer
Merck
Sublocade
Indivior
Flag link:
Ionis Sends Nerve Drug to Spinout Akcea as Battle with Alnylam Looms
Ionis Sends Nerve Drug to Spinout Akcea as Battle with Alnylam Looms
Xconomy
Ionis Pharmaceuticals
Akcea
Alnylam
transthyretin amyloidosis
inotersen
IONIS-TTR-Lrx
Flag link:
A biopharma CEO's 5 wishes for Trump’s State of the Union address
A biopharma CEO's 5 wishes for Trump’s State of the Union address
Stat
Donald Trump
John Maraganore
Alnylam
drug pricing
FDA
HHS
healthcare reform
opioid crisis
Flag link:
Three Interviews From the J.P. Morgan Healthcare Conference
Three Interviews From the J.P. Morgan Healthcare Conference
Motley Fool
JPMHC 2018
Alnylam
Arena Pharmaceuticals
Spark Therapeutics
Flag link:
Will 2018 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?
Will 2018 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?
Yahoo/Motley Fool
Alnylam
givosiran
Patisiran
Flag link:
Alnylam kicks off #JPM18 with a restructured Sanofi deal, grabbing global rights to patisiran
Alnylam kicks off #JPM18 with a restructured Sanofi deal, grabbing global rights to patisiran
Endpoints
Alnylam
Sanofi
JPMHC 2018
Patisiran
Flag link:
Alnylam, Sanofi given the all-clear to resume fitusiran trials
Alnylam, Sanofi given the all-clear to resume fitusiran trials
BioPharma Dive
Alnylam
Sanofi
clinical trials
fitusiran
hemophilia
Flag link:
8 Takeout targets to watch in 2018
8 Takeout targets to watch in 2018
BioPharma Dive
M&A
Allergan
Alnylam
Biomarin
Bristol-Myers Squibb
Incyte
Madrigal Pharmaceuticals
Spark Therapeutics
Sucampo
Flag link:
Four months after patient death, FDA’s hold lifted on Alnylam’s fitusiran
Four months after patient death, FDA’s hold lifted on Alnylam’s fitusiran
Endpoints
patients
FDA
Alnylam
fitusiran
Flag link:
FDA adds ‘breakthrough’ status for Alnylam as patisiran starts its victory lap at the agency
FDA adds ‘breakthrough’ status for Alnylam as patisiran starts its victory lap at the agency
Endpoints
FDA
Alnylam
Patisiran
breakthrough status
Flag link:
Alnylam Starts Rolling NDA Submission for RNAi Candidate
Alnylam Starts Rolling NDA Submission for RNAi Candidate
Yahoo/Zacks.com
Alnylam
RNAi
hereditary ATTR amyloidosis
FDA
Patisiran
Flag link:
Alnylam outshines Ionis with RNAi drug
Alnylam outshines Ionis with RNAi drug
BioPharma Dive
Alnylam
Ionis Pharmaceuticals
RNAi
Sanofi
Patisiran
amyloidosis
Flag link:
The Medicine Company's Dangerous Bet On Its LDL Cholesterol Lowering Drug
The Medicine Company's Dangerous Bet On Its LDL Cholesterol Lowering Drug
Forbes
The Medicine Company
LDL cholesterol
inclisiran
Alnylam
PCSK9 inhibitors
Flag link:
With $500M-plus, a buyout and two new billion-dollar pacts, upstart Vir is ready to roll on infectious diseases
With $500M-plus, a buyout and two new billion-dollar pacts, upstart Vir is ready to roll on infectious diseases
Endpoints
Vir Biotechnology
George Scangos
Alnylam
Visterra
Flag link:
A drug 15 years in the making: Alnylam's quest to prove RNAi
A drug 15 years in the making: Alnylam's quest to prove RNAi
BioPharma Dive
Alnylam
RNAi
Patisiran
Flag link:

Pages